Hospital Diabetes Meeting 2022
- PMID: 35904143
- PMCID: PMC9445340
- DOI: 10.1177/19322968221110878
Hospital Diabetes Meeting 2022
Abstract
The annual Virtual Hospital Diabetes Meeting was hosted by Diabetes Technology Society on April 1 and April 2, 2022. This meeting brought together experts in diabetes technology to discuss various new developments in the field of managing diabetes in hospitalized patients. Meeting topics included (1) digital health and the hospital, (2) blood glucose targets, (3) software for inpatient diabetes, (4) surgery, (5) transitions, (6) coronavirus disease and diabetes in the hospital, (7) drugs for diabetes, (8) continuous glucose monitoring, (9) quality improvement, (10) diabetes care and educatinon, and (11) uniting people, process, and technology to achieve optimal glycemic management. This meeting covered new technology that will enable better care of people with diabetes if they are hospitalized.
Keywords: continuous glucose monitor; diabetes; electronic health record; hospital; insulin; technology.
Conflict of interest statement
JJS has received remuneration for participation in one Advisory Board meeting for Dexcom.
GEU reports research funds to Emory University from Dexcom, Abbott, and Bayer.
AW reports research support from Novo Nordisk, UnitedHealth Group, and Eli Lilly.
MCL reports research funding from Dexcom.
UM reports research funding from Clementia Pharmaceutical and is an advisor for Ryse Health.
FJP has received unrestricted research support from Merck, Dexcom, and Insulet and consulting fees from Merck, Boehringer Ingelheim, Lilly, Medscape, and Dexcom.
VNS reports receiving research funding through University of Colorado from Dexcom Inc, Eli Lilly, NovoNorisk, Tandem Diabetes Care, and Insulet outside the submitted work. VNS’ employer, University of Colorado, received honoraria/consulting/speaking fees from Sanofi, Medscape, Lifescan, Dexcom, and Insulet.
EKS reports that this work was supported in part by a VA MERIT award from the US Department of Veterans Affairs Clinical Sciences Research and Development Service (1I01CX001825). He has received unrestricted research support from Dexcom (to the Baltimore VA Medical Center and to the University of Maryland) for the conduction of clinical trials.
DCK is a consultant to EOFlow, Fractyl Health, Integrity, Lifecare, Rockley Photonics, and Thirdwayv.
JH, AMY, KTN, NYX, RJR, ATD, RG, NNM, SS, AS, and GMT have nothing to disclose.
Figures
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
